GlassScriptPhysician profile
Peter I Oppenheim
NPI 1770567513
$9,897.07
in general payments reported to CMS, 2019-2025
50 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $439 · 2021: $823 · 2022: $1,464 · 2023: $2,375 · 2024: $1,718 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,592.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,758.00 | 2019-2025 | |
| Novo Nordisk INC | $1,044.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $989.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $897.54 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $774.65 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $730.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $577.90 | 2019-2025 | |
| Allergan, INC. | $292.52 | 2019-2020 | |
| Abbott Laboratories | $267.90 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $261.42 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $254.30 | 2019-2025 | |
| Mylan Specialty L.P. | $241.56 | 2022-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $211.28 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.15 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $140.17 | 2019-2025 | Eliquis, Camzyos |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Oppenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.